分子腫瘤診斷市場－策略分析與預測（2026-2035）

預計分子腫瘤診斷市場將從 2026 年的 47.5 億美元成長到 2035 年的 105.1 億美元，複合年成長率為 9.2%。

隨著精準醫療革新癌症診斷和治療，全球分子腫瘤診斷市場正經歷快速成長。分子腫瘤診斷利用先進的基因組學和分子生物學技術，識別與各種癌症相關的基因突變、生物標記、基因表現模式和其他分子變化。這些診斷技術使臨床醫生能夠更早發現癌症、選擇標靶治療、監測疾病進展、評估治療效果，並以比傳統方法更高的準確度識別復發。日益加重的全球癌症負擔、個人化醫療的日益普及以及基因組技術的不斷進步，都推動了對分子腫瘤診斷解決方案的強勁需求。

該市場涵蓋分子診斷儀器、試劑、檢測試劑盒、軟體、定序平台、伴隨診斷和檢查室服務。次世代定序(NGS)、聚合酵素鏈鎖反應(PCR)、數位 PCR、螢光雜合反應(FISH)、液態生物檢體和多分子檢測技術的持續創新顯著提高了分析靈敏度、縮短了檢測反應時間並增強了臨床效用。這些技術能夠對腫瘤進行全面的基因組分析，從而支持制定個人化治療方案並改善患者預後。

隨著標靶治療的日益普及，分子診斷在腫瘤學領域的重要性顯著提升。製藥公司越來越需要伴隨診斷檢測，以識別最有可能從特定癌症治療中受益的患者。此外，液態生物檢體在非侵入性癌症檢測和疾病監測中的應用不斷擴展，減少了對外科組織切片檢查的依賴，從而改變了臨床實踐。對癌症研發投入的增加、對精準醫療的有利監管支持以及多個已開發市場保險覆蓋範圍的擴大，都持續推動著該行業的成長。

全球醫療機構正在對其檢查室基礎設施進行現代化改造，並將分子檢測納入常規腫瘤診療流程。學術研究機構、生物技術公司、製藥企業和合約研究組織也在擴大分子腫瘤診斷的應用範圍，用於生物標記發現、臨床試驗患者篩選和治療監測。隨著基因組醫學的不斷發展，預計在預測期內，分子腫瘤診斷將成為綜合癌症管理不可或缺的一部分。

市場促進因素

全球癌症負擔日益加重

乳癌、肺癌、大腸癌、攝護腺癌、骨髓惡性腫瘤和其他固體癌率的不斷上升，推動了對高精確度分子診斷技術的需求。早期分子診斷有助於及時啟動治療，進而提高患者的存活率。

精準醫療的廣泛應用

醫療專業人員正擴大利用基因組資訊來實現癌症治療的個人化。分子診斷能夠識別具有治療意義的基因突變，使臨床醫生能夠根據個別腫瘤的生物學特徵選擇標靶治療。

基因組技術的進步

次世代定序、數位PCR、液態生物檢體、多分子檢測和生物資訊學的不斷進步，正在提高診斷準確性，縮短檢測時間，並擴大臨床應用範圍。

伴隨診斷的擴展

隨著標靶癌症療法的研發管線不斷擴大，對能夠識別合格的患者群體並改善治療效果的伴隨診斷測試的需求也日益成長。

加大對癌症研究的投資

各國政府、生技公司、製藥企業和研究機構繼續大力投資癌症基因組學、生物標記發現和分子醫學，從而支持市場的長期成長。

市場限制因素

分子檢測高成本

先進的分子診斷平台和全面的基因組分析仍然價格昂貴，限制了財政資源有限的醫療保健系統採用這些技術。

複雜的監管要求

分子診斷產品需要廣泛的臨床檢驗和監管部門的批准，這會增加研發成本並延長上市時間。

發展中地區資源取得有限

許多中低收入國家的醫療機構缺乏進行先進分子檢測所需的檢查室基礎設施、專用設備和訓練有素的人員。

數據解讀的挑戰

全面的基因組分析會產生大量的複雜分子數據，需要先進的生物資訊工具和訓練有素的專家才能準確解讀。

保險報銷差異

各國報銷政策的差異持續影響先進分子腫瘤診斷技術的取得及其在常規臨床實務中的應用。

目錄

第1章執行摘要

• 市場概述
• 主要分析結果
• 分析師意見
• 策略建議

第2章 分析方法

• 分析設計
• 資料收集和分析方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章：分子腫瘤診斷市場：概述、市場規模與未來預測

• 市場定義和範圍
• 分子腫瘤診斷概述
• 產業變化
• 主要市場趨勢
• 市場規模表現分析
• 市場預測
• 癌症負擔和診斷需求分析
• 腫瘤學中的分子生物標記
• 流行病學和癌症發生率分析
• 已確診患者族群的分析
• 腫瘤檢查數量分析
• 精準腫瘤治療現狀
• 患者就診流程和分子檢測路徑
• 臨床未滿足的需求

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• 新興技術
• 產品創新
• 臨床試驗分析
• 管道分析
• 技術藍圖
• 將人工智慧應用於分子腫瘤診斷
• 數位病理學與數位健康的融合

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章：分子腫瘤診斷市場：展望分析

• 分析：按技術
• 分析：依生物標記類型
• 分析：依樣本類型
• 分析：按癌症類型分類
• 分析：透過分析方法
• 分析：透過臨床應用
• 分析：按最終用戶

第9章 分子腫瘤診斷市場：細分市場分析

• 透過技術
  • 聚合酵素鏈鎖反應（PCR）
  • 次世代定序（NGS）
  • 螢光原位雜合反應（FISH）
  • 免疫組織化學（IHC）
  • 流式細胞技術
  • 其他
• 依樣本類型
  • 組織切片檢查
  • 液態生物檢體
    • 全血
    • 電漿
    • 血清
    • 其他
  • 骨髓
  • 其他體液
• 按癌症類型
  • 乳癌
  • 肺癌
  • 結腸癌
  • 骨髓惡性腫瘤
  • 其他固體癌
• 透過使用
  • 臨床診斷
    • 癌症篩檢
    • 診斷
    • 預後
    • 伴隨診斷
    • 治療方案
    • 其他
  • 分析用途
    • 藥物研發
    • 生物市場發現
    • 臨床試驗支持
    • 其他
• 最終用戶
  • 醫院和診斷中心
  • 診斷檢查室
  • 製藥和生物技術公司
  • 癌症研究機構
  • 其他

第10章 分子腫瘤診斷市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章：分子腫瘤診斷市場：國別分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 荷蘭
• 瑞士
• 日本
• 中國
• 印度
• 韓國
• 澳洲
• 巴西
• 沙烏地阿拉伯

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 併購、合作與聯盟
• 新產品發布

第13章：公司簡介

• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Guardant Health Inc.
• Tempus
• Natera Inc.
• NeoGenomics
• Siemens AG
• Danaher Corporation
• Abbott Laboratories

第14章：分子腫瘤診斷市場：商業預測分析

第15章 投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The Molecular Oncology Diagnostics Market is expected to grow at a CAGR of 9.2% from a market value of USD 4.75 billion in 2026 to USD 10.51 billion in 2035.

The global molecular oncology diagnostics market is experiencing rapid growth as precision medicine transforms cancer diagnosis and treatment. Molecular oncology diagnostics utilize advanced genomic and molecular technologies to identify genetic mutations, biomarkers, gene expression patterns, and other molecular alterations associated with various cancers. These diagnostic approaches enable clinicians to detect cancer at earlier stages, select targeted therapies, monitor disease progression, assess treatment response, and identify recurrence with greater accuracy than conventional diagnostic methods. The increasing global burden of cancer, growing adoption of personalized medicine, and continuous advancements in genomic technologies are driving strong demand for molecular oncology diagnostic solutions.

The market includes molecular diagnostic instruments, reagents, assay kits, software, sequencing platforms, companion diagnostics, and laboratory services. Continuous innovation in next-generation sequencing (NGS), polymerase chain reaction (PCR), digital PCR, fluorescence in situ hybridization (FISH), liquid biopsy, and multiplex molecular assays has significantly improved analytical sensitivity, turnaround time, and clinical utility. These technologies enable comprehensive genomic profiling of tumors while supporting individualized treatment planning and improved patient outcomes.

Growing adoption of targeted therapies has significantly increased the importance of molecular diagnostics in oncology. Pharmaceutical companies increasingly require companion diagnostic tests to identify patients most likely to benefit from specific cancer therapies. In addition, expanding applications of liquid biopsy for non-invasive cancer detection and disease monitoring are reshaping clinical practice by reducing dependence on surgical tissue biopsies. Increasing investment in cancer research, favorable regulatory support for precision medicine, and expanding reimbursement coverage in several developed markets continue to strengthen industry growth.

Healthcare providers worldwide are modernizing laboratory infrastructure and integrating molecular testing into routine oncology care. Academic research institutions, biotechnology companies, pharmaceutical manufacturers, and contract research organizations are also increasing utilization of molecular oncology diagnostics for biomarker discovery, clinical trial patient selection, and therapeutic monitoring. As genomic medicine continues to advance, molecular oncology diagnostics are expected to become an essential component of comprehensive cancer management throughout the forecast period.

Market Drivers

Rising Global Cancer Burden

The increasing incidence of breast cancer, lung cancer, colorectal cancer, prostate cancer, hematological malignancies, and other solid tumors is driving demand for highly accurate molecular diagnostic technologies. Early molecular diagnosis supports timely treatment initiation and improves survival outcomes.

Growing Adoption of Precision Medicine

Healthcare providers are increasingly utilizing genomic information to personalize cancer treatment. Molecular diagnostics enable identification of actionable genetic mutations, allowing clinicians to select targeted therapies based on individual tumor biology.

Advancements in Genomic Technologies

Continuous improvements in next-generation sequencing, digital PCR, liquid biopsy, multiplex molecular testing, and bioinformatics are enhancing diagnostic accuracy, reducing testing time, and expanding clinical applications.

Expansion of Companion Diagnostics

The growing pipeline of targeted oncology therapies has increased demand for companion diagnostic tests that identify eligible patient populations and improve treatment outcomes.

Increasing Investments in Oncology Research

Governments, biotechnology companies, pharmaceutical manufacturers, and research institutions continue to invest heavily in cancer genomics, biomarker discovery, and molecular medicine, supporting long-term market growth.

Market Restraints

High Cost of Molecular Testing

Advanced molecular diagnostic platforms and comprehensive genomic profiling remain expensive, limiting adoption in healthcare systems with constrained financial resources.

Complex Regulatory Requirements

Molecular diagnostic products require extensive clinical validation and regulatory approval, increasing development costs and extending commercialization timelines.

Limited Access in Developing Regions

Many healthcare facilities in low- and middle-income countries lack the laboratory infrastructure, specialized equipment, and trained personnel necessary for advanced molecular testing.

Data Interpretation Challenges

Comprehensive genomic profiling generates large volumes of complex molecular data that require advanced bioinformatics tools and highly trained specialists for accurate interpretation.

Reimbursement Variability

Differences in reimbursement policies across countries continue to affect accessibility and routine clinical adoption of advanced molecular oncology diagnostics.

Technology and Segment Insights

The molecular oncology diagnostics market can be segmented by product, technology, application, cancer type, end user, and geography.

By Product

Reagents and assay kits account for the largest share of the market because they are required for every molecular diagnostic test. Continuous growth in testing volumes generates recurring demand for high-quality reagents, primers, probes, controls, and sequencing consumables.

Diagnostic instruments continue to experience strong growth as laboratories invest in automated sequencing systems, PCR platforms, digital PCR instruments, and integrated molecular diagnostic analyzers.

Software and bioinformatics platforms are becoming increasingly important for genomic data analysis, variant interpretation, laboratory workflow management, and clinical reporting.

By Technology

Next-generation sequencing represents one of the fastest-growing technology segments because it enables comprehensive genomic profiling, mutation detection, and precision oncology applications.

Polymerase chain reaction remains widely utilized due to its speed, accuracy, affordability, and broad applicability across oncology diagnostics.

Digital PCR continues to gain importance for highly sensitive mutation detection and minimal residual disease monitoring.

Fluorescence in situ hybridization, microarray technologies, and liquid biopsy platforms continue to expand their role in comprehensive molecular cancer diagnostics.

By Application

Cancer diagnosis remains the largest application segment as molecular diagnostics support early detection, accurate tumor classification, and disease staging.

Companion diagnostics represent a rapidly expanding segment driven by increasing approval of targeted oncology therapies.

Treatment monitoring and recurrence detection continue to gain momentum as clinicians increasingly utilize circulating tumor DNA and molecular biomarkers to evaluate therapeutic response.

Research applications also contribute significantly through biomarker discovery, clinical trials, translational medicine, and pharmaceutical development.

By Cancer Type

Lung cancer represents a major application area due to widespread use of EGFR, ALK, ROS1, KRAS, and other biomarker testing.

Breast cancer continues to generate substantial demand through HER2, BRCA, and genomic expression profiling.

Colorectal, prostate, hematological, ovarian, melanoma, and other cancers increasingly rely on molecular diagnostics to support personalized treatment selection.

By End User

Hospitals represent the largest end-user segment because of increasing integration of molecular diagnostics into routine oncology care.

Independent diagnostic laboratories continue to strengthen market demand by providing specialized genomic testing services.

Academic research institutes, biotechnology companies, pharmaceutical organizations, and contract research organizations extensively utilize molecular diagnostics for oncology research and drug development.

By Geography

North America dominates the market owing to advanced healthcare infrastructure, widespread adoption of precision medicine, strong reimbursement systems, and significant investment in cancer genomics.

Europe continues to experience steady growth supported by established oncology care networks, expanding genomic medicine initiatives, and increasing healthcare investments.

Asia Pacific is expected to witness the fastest growth due to rising cancer incidence, expanding healthcare infrastructure, increasing government investment in precision medicine, and improving access to advanced molecular diagnostics.

Latin America and the Middle East & Africa are gradually strengthening their molecular diagnostic capabilities through healthcare modernization and laboratory expansion initiatives.

Competitive and Strategic Outlook

The competitive landscape includes molecular diagnostics companies, biotechnology firms, genomic sequencing providers, medical device manufacturers, pharmaceutical companies, and healthcare technology organizations. Competition is centered on improving analytical accuracy, expanding biomarker panels, increasing laboratory automation, enhancing bioinformatics capabilities, and developing integrated precision oncology solutions.

Manufacturers continue to invest in next-generation sequencing platforms, liquid biopsy technologies, artificial intelligence-enabled genomic analysis, digital pathology integration, and companion diagnostics. Strategic collaborations between pharmaceutical companies and diagnostic manufacturers are accelerating biomarker validation and expanding the availability of targeted cancer therapies. Product launches, acquisitions, research partnerships, regulatory approvals, and international expansion remain key strategies for strengthening market position.

Conclusion

The global molecular oncology diagnostics market is expected to witness substantial growth throughout the forecast period, driven by increasing cancer prevalence, expanding precision medicine initiatives, rapid advancements in genomic technologies, and growing adoption of targeted therapies. Innovations in next-generation sequencing, liquid biopsy, digital PCR, artificial intelligence, and bioinformatics are transforming cancer diagnosis by enabling highly accurate molecular profiling and personalized treatment selection. Although high testing costs, regulatory challenges, reimbursement variability, and infrastructure limitations remain significant barriers, ongoing investment in cancer research and healthcare modernization is expected to support long-term market expansion. Molecular oncology diagnostics will continue to play a central role in precision oncology by enabling earlier diagnosis, optimized therapeutic decision-making, improved disease monitoring, and enhanced patient outcomes.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Molecular Oncology Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Overview of Molecular Oncology Diagnostics
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Cancer Burden and Diagnostic Demand Analysis
• 3.8 Molecular Biomarkers in Oncology
• 3.9 Epidemiology and Cancer Incidence Analysis
• 3.10 Diagnosed Patient Population Analysis
• 3.11 Oncology Testing Volume Analysis
• 3.12 Precision Oncology Treatment Landscape
• 3.13 Patient Journey and Molecular Testing Pathway
• 3.14 Unmet Clinical Needs

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Technology Roadmap
• 6.6 Artificial Intelligence Integration in Molecular Oncology Diagnostics
• 6.7 Digital Pathology and Digital Health Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Molecular Oncology Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Cancer Type
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by Clinical Application
• 8.7 Analysis by End User

9. Molecular Oncology Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Technology
  • 9.1.1 Polymerase Chain Reaction (PCR)
  • 9.1.2 Next-Generation Sequencing (NGS)
  • 9.1.3 Fluorescence In Situ Hybridization (FISH)
  • 9.1.4 Immunohistochemistry (IHC)
  • 9.1.5 Flow Cytometry
  • 9.1.6 Others
• 9.3 By Sample Type
  • 9.3.1 Tissue Biopsy
  • 9.3.2 Liquid Biopsy
    • 9.3.2.1 Whole Blood
    • 9.3.2.2 Plasma
    • 9.3.2.3 Serum
    • 9.3.2.4 Others
  • 9.3.3 Bone Marrow
  • 9.3.4 Other Body Fluids
• 9.4 By Cancer Type
  • 9.4.1 Breast Cancer
  • 9.4.2 Lung Cancer
  • 9.4.3 Colorectal Cancer
  • 9.4.4 Hematologic Malignancies
  • 9.4.5 Other Solid Tumors
• 9.5 By Application
  • 9.5.1 Clinical Diagnostics
    • 9.5.1.1 Cancer Screening
    • 9.5.1.2 Diagnosis
    • 9.5.1.3 Prognosis
    • 9.5.1.4 Companion Diagnostics
    • 9.5.1.5 Therapy Selection
    • 9.5.1.6 Others
  • 9.5.2 Research Use
    • 9.5.2.1 Drug Development
    • 9.5.2.2 Biomarket Discovery
    • 9.5.2.3 Clinical Trials Support
    • 9.5.2.4 Others
• 9.6 By End User
  • 9.6.1 Hospitals & Diagnostic Centers
  • 9.6.2 Diagnostic Laboratories
  • 9.6.3 Pharmaceutical and Biotechnology Companies
  • 9.6.4 Cancer Research Institutes
  • 9.6.5 Others

10. Molecular Oncology Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Molecular Oncology Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Switzerland
• 11.10 Japan
• 11.11 China
• 11.12 India
• 11.13 South Korea
• 11.14 Australia
• 11.15 Brazil
• 11.16 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Illumina, Inc.
• 13.3 Thermo Fisher Scientific Inc.
• 13.4 Guardant Health Inc.
• 13.5 Tempus
• 13.6 Natera Inc.
• 13.7 NeoGenomics
• 13.8 Siemens AG
• 13.9 Danaher Corporation
• 13.10 Abbott Laboratories

14. Molecular Oncology Diagnostics Market Commercial Forecast Analysis

• 14.1 Next-Generation Sequencing-Based Oncology Diagnostics
• 14.2 PCR-Based Oncology Diagnostics
• 14.3 Liquid Biopsy Diagnostics
• 14.4 Companion Diagnostic Assays
• 14.5 Comprehensive Genomic Profiling Tests
• 14.6 Minimal Residual Disease (MRD) Diagnostics
• 14.7 Multi-Gene Cancer Panel Diagnostics

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends